Λοιπόν, ξεκινάμε.
Παλαιότερα έκανα μια απλή αναφορά σε αυτό το πεπτίδιο,τώρα θα επεκταθώ εκτενέστερα στην συγκεκριμένη ουσία,έχοντας πλέον συγκεντρώσει αρκετές πληροφορίες για αυτήν.
Τι είναι το bnp-32 ;
-Το bnp-32 είναι όπως έχω πει ένα πεπτίδιο.
Είναι το bnp κάτι καινούριο ;
-Όχι.Είναι και η κύρια ουσία του φαρμάκου NESIRITIDE που χρησιμοποιείται για την καρδιακή ανεπάρκεια.
Πώς γνωρίζουμε ότι μπορεί να χρησιμεύσει στην τριχόπτωση ;
-Με μια νέα πατέντα ενός Ιάπωνα ημερομηνίας Σεπτεμβρίου του 2012.
Για ποιών ειδών τριχόπτωσης μιλάμε ;
-Το bnp χρησιμοποιήθηκε μόνο σε περιπτώσεις ανδρογενετικής αλωπεκίας. Διαφοροποιήσεις όμως του πεπτιδίου bnp ,όπως το cnp και το anp, χρησιμοποιήθηκαν και στην γυροειδή αλωπεκία αλλά και στην τριχόπτωση που αφορά τις γυναίκες.
Πόσο καιρό χρησιμοποιήθηκε σε άτομα στην πατέντα ;
-Από μία εβδομάδα έως και ένα μήνα.
Ποια ήταν τα αποτελέσματα του ;
-Ελαχιστοποίηση τριχόπτωσης ,επανέκφυση,ελαχιστοποίηση σμήγματος.
Υπήρχαν παρενέργειες ;
-Καμία δεν αναφέρθηκε.
Για όποιον επιθυμεί να διαβάσει το πρωτότυπο της πατέντας: http://www.faqs.org/patents/app/20120238498#ixzz2GS8ovuPN
Φωτογραφίες: Ανδρογενετική Αλωπεκία
http://www.faqs.org/patents/imgfull/20120238498_50
http://www.faqs.org/patents/imgfull/20120238498_51
http://www.faqs.org/patents/imgfull/20120238498_46
Γυροειδής Αλωπεκία
http://www.faqs.org/patents/imgfull/20120238498_64
http://www.faqs.org/patents/imgfull/20120238498_63
Από την πατέντα:
As a result of an intensive investigation by the present inventors in light of the above-mentioned circumstances, it has been found that an A-type natriuretic peptide (ANP) known as an acute heart failure treatment drug, a B-type natriuretic peptide (BNP) known as a congestive heart failure treatment drug, and a C-type natriuretic peptide (CNP) conventionally known as a vascular smooth muscle growth inhibitor, etc. have excellent effectiveness and safety as agents for the treatment and/or prevention of alopecia, dandruff, white hair, and seborrheic scalp.
[0666] As is clear from the above-mentioned test cases, the agent for the treatment of alopecia of the present invention had a very high recovery rate for hair loss, and the period taken to express its hair growth promoting effect was short. In most cases, hair growth was confirmed by applying the agent for the treatment of alopecia of the present invention for 1 week to 2 weeks, and clear hair growth was observed during the 3rd week. Furthermore, the treatment agent of the present invention restored white hair to black hair, decreased dandruff in an alopecia pityroides patient, and improved seborrheic scalp in a seborrheic alopecia patient.
[0667] When the agent for the treatment of alopecia of the present invention contained CNP or BNP as an active ingredient, the therapeutic effects were marked, hair grew almost certainly with application twice a day for 1 week, terminal hair was observed with application for 2 weeks, and it became difficult to see the skin with application for 4 weeks. Worthy of special note is that it was unnecessary to continue application after vellus hair grew; the vellus hair became dark and thick, became terminal hair, and continued to grow.
[0671] These therapeutic effects of the present invention in the treatment of androgenetic alopecia were in marked contrast to the fact that in a group that has had orally administered finasteride for 1 year and has then stopped administration, the improvement effect disappears and androgenetic alopecia progresses. That is, the effect of finasteride is seen only while it is being orally administered, whereas with external application of the agent for the treatment of alopecia of the present invention for 1 to 3 weeks, the improved hair growth state could be maintained for about 2 months after its use was stopped. After 3 months had elapsed since application of the agent for the treatment of alopecia of the present invention was stopped, there was a case in which the original hair loss state returned, but even in this case reapplying the agent for the treatment of alopecia of the present invention allowed the same black terminal hair to grow as previously without side effects.
[0673] Moreover, BNP and CNP did not exhibit any adverse events such as local symptoms of irritation, skin atrophy, or an itching sensation resulting from their application, and there were no systemic side effects
[0691] Therefore, the agent for the treatment of alopecia of the present invention can be anticipated to be useful as a very effective treatment drug for alopecia for which sufficient therapeutic effects cannot be obtained by the conventional minoxidil or finasteride, and alopecia that develops in relation to an immune overreaction or an immune abnormality.
Παλαιότερα έκανα μια απλή αναφορά σε αυτό το πεπτίδιο,τώρα θα επεκταθώ εκτενέστερα στην συγκεκριμένη ουσία,έχοντας πλέον συγκεντρώσει αρκετές πληροφορίες για αυτήν.
Τι είναι το bnp-32 ;
-Το bnp-32 είναι όπως έχω πει ένα πεπτίδιο.
Είναι το bnp κάτι καινούριο ;
-Όχι.Είναι και η κύρια ουσία του φαρμάκου NESIRITIDE που χρησιμοποιείται για την καρδιακή ανεπάρκεια.
Πώς γνωρίζουμε ότι μπορεί να χρησιμεύσει στην τριχόπτωση ;
-Με μια νέα πατέντα ενός Ιάπωνα ημερομηνίας Σεπτεμβρίου του 2012.
Για ποιών ειδών τριχόπτωσης μιλάμε ;
-Το bnp χρησιμοποιήθηκε μόνο σε περιπτώσεις ανδρογενετικής αλωπεκίας. Διαφοροποιήσεις όμως του πεπτιδίου bnp ,όπως το cnp και το anp, χρησιμοποιήθηκαν και στην γυροειδή αλωπεκία αλλά και στην τριχόπτωση που αφορά τις γυναίκες.
Πόσο καιρό χρησιμοποιήθηκε σε άτομα στην πατέντα ;
-Από μία εβδομάδα έως και ένα μήνα.
Ποια ήταν τα αποτελέσματα του ;
-Ελαχιστοποίηση τριχόπτωσης ,επανέκφυση,ελαχιστοποίηση σμήγματος.
Υπήρχαν παρενέργειες ;
-Καμία δεν αναφέρθηκε.
Για όποιον επιθυμεί να διαβάσει το πρωτότυπο της πατέντας: http://www.faqs.org/patents/app/20120238498#ixzz2GS8ovuPN
Φωτογραφίες: Ανδρογενετική Αλωπεκία
http://www.faqs.org/patents/imgfull/20120238498_50
http://www.faqs.org/patents/imgfull/20120238498_51
http://www.faqs.org/patents/imgfull/20120238498_46
Γυροειδής Αλωπεκία
http://www.faqs.org/patents/imgfull/20120238498_64
http://www.faqs.org/patents/imgfull/20120238498_63
Από την πατέντα:
As a result of an intensive investigation by the present inventors in light of the above-mentioned circumstances, it has been found that an A-type natriuretic peptide (ANP) known as an acute heart failure treatment drug, a B-type natriuretic peptide (BNP) known as a congestive heart failure treatment drug, and a C-type natriuretic peptide (CNP) conventionally known as a vascular smooth muscle growth inhibitor, etc. have excellent effectiveness and safety as agents for the treatment and/or prevention of alopecia, dandruff, white hair, and seborrheic scalp.
[0666] As is clear from the above-mentioned test cases, the agent for the treatment of alopecia of the present invention had a very high recovery rate for hair loss, and the period taken to express its hair growth promoting effect was short. In most cases, hair growth was confirmed by applying the agent for the treatment of alopecia of the present invention for 1 week to 2 weeks, and clear hair growth was observed during the 3rd week. Furthermore, the treatment agent of the present invention restored white hair to black hair, decreased dandruff in an alopecia pityroides patient, and improved seborrheic scalp in a seborrheic alopecia patient.
[0667] When the agent for the treatment of alopecia of the present invention contained CNP or BNP as an active ingredient, the therapeutic effects were marked, hair grew almost certainly with application twice a day for 1 week, terminal hair was observed with application for 2 weeks, and it became difficult to see the skin with application for 4 weeks. Worthy of special note is that it was unnecessary to continue application after vellus hair grew; the vellus hair became dark and thick, became terminal hair, and continued to grow.
[0671] These therapeutic effects of the present invention in the treatment of androgenetic alopecia were in marked contrast to the fact that in a group that has had orally administered finasteride for 1 year and has then stopped administration, the improvement effect disappears and androgenetic alopecia progresses. That is, the effect of finasteride is seen only while it is being orally administered, whereas with external application of the agent for the treatment of alopecia of the present invention for 1 to 3 weeks, the improved hair growth state could be maintained for about 2 months after its use was stopped. After 3 months had elapsed since application of the agent for the treatment of alopecia of the present invention was stopped, there was a case in which the original hair loss state returned, but even in this case reapplying the agent for the treatment of alopecia of the present invention allowed the same black terminal hair to grow as previously without side effects.
[0673] Moreover, BNP and CNP did not exhibit any adverse events such as local symptoms of irritation, skin atrophy, or an itching sensation resulting from their application, and there were no systemic side effects
[0691] Therefore, the agent for the treatment of alopecia of the present invention can be anticipated to be useful as a very effective treatment drug for alopecia for which sufficient therapeutic effects cannot be obtained by the conventional minoxidil or finasteride, and alopecia that develops in relation to an immune overreaction or an immune abnormality.
